ONCY$0.391-2.25%
Oncolytics Biotech Inc.
Sector: Pharmaceutical PreparationsIndustry: BiotechnologyCountry: USExchange: Nasdaq
Mkt Cap:$49.86M
Float & O/S:
Inst Own:
DilutionScan read 36 of ONCOLYTICS BIOTECH INC's SEC filings and found 3 warrant series, 4 ATM programs, 1 equity line and 3 shelf registrations on file for ONCY. The latest dilution event on file is ATM sales on Aug 10, 2026. Analysis updated Oct 4, 2026.
Signal8 Summary
ONCY
Going-concern warning from auditors
Snapshot
Oncolytics is a clinical-stage biotechnology company that currently generates no revenue and burns roughly $20M a year. The company holds only $5.1M in cash, which is not enough to fund operations for the next year, triggering a formal going-concern warning from auditors.
What's Happening Right Now
- : The FDA granted Fast Track designation to pelareorep in combination with a checkpoint inhibitor for second-line anal cancer, targeting a market with an estimated $1B annual opportunity where no approved therapies currently exist.
- : The company disclosed a going-concern warning in its Q1 2026 10-Q, stating its $5.5M cash position is insufficient to fund planned operations for the next twelve months without additional financing.
- : The company reported durable responses for pelareorep in second-line RAS-mutant MSS colorectal cancer, with a median duration of response of 19.5 months, a 3-4x improvement over historical benchmarks.
